Updated Recommendations on Treatment of Adolescents and Children with Chronic HCV Infection, and HCV Simplified Service Delivery and Diagnostics [Internet]
- PMID: 37410875
- Bookshelf ID: NBK592813
Updated Recommendations on Treatment of Adolescents and Children with Chronic HCV Infection, and HCV Simplified Service Delivery and Diagnostics [Internet]
Excerpt
This policy brief focuses on the new recommendations on treatment of adolescents and children aged 3 years or older with chronic hepatitis C virus (HCV) infection.
The new treatment recommendations that extend the 2018 treat all recommendation for adults with chronic HCV infection to include adolescents and children down to 3 years, and to align the existing recommended pangenotypic direct-acting antiviral (DAA) regimens (SOF/DCV, SOF/VEL and G/P) for adults, to those for adolescents and children. This alignment is expected to simplify procurement, promote access to treatment among children in low- and middle-income countries and contribute to global efforts to eliminate the disease.
© World Health Organization 2022.
Sections
- Acknowledgements
- Abbreviations
- Glossary
- Executive Summary
- Summary of Recommendations
- CHAPTER 1. Introduction
- CHAPTER 2. Background – Epidemiology and Natural History
- CHAPTER 3. Methodology and Process of Developing the Guidelines
- Treatment of Adults, Adolescents and Children ≥ 3 Years
- Simplified Service Delivery for a Public Health Approach to HCV Testing, Care and Treatment
- HCV Diagnostics
- References
- WEB ANNEX A. Summary of Declarations of Conflicts of Interest
- WEB ANNEX B. Evidence-to-Decision-Making Tables and Grade Tables
- Web Annex C. Systematic Review Reports
- Web Annex D. Systematic Review Reports
Similar articles
-
Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.J Hepatol. 2019 Jan;70(1):15-23. doi: 10.1016/j.jhep.2018.09.018. Epub 2018 Sep 26. J Hepatol. 2019. PMID: 30266283
-
Pangenotypic direct-acting antiviral agents for mixed genotype hepatitis C infection: A real-world effectiveness analysis.J Gastroenterol Hepatol. 2021 Oct;36(10):2911-2916. doi: 10.1111/jgh.15546. Epub 2021 May 19. J Gastroenterol Hepatol. 2021. PMID: 33978973
-
High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar.J Viral Hepat. 2019 Oct;26(10):1186-1199. doi: 10.1111/jvh.13133. Epub 2019 Jun 10. J Viral Hepat. 2019. PMID: 31104344
-
Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials.Ther Clin Risk Manag. 2017 Apr 12;13:477-497. doi: 10.2147/TCRM.S134818. eCollection 2017. Ther Clin Risk Manag. 2017. PMID: 28442915 Free PMC article. Review.
-
Meeting the WHO hepatitis C virus elimination goal: Review of treatment in paediatrics.J Viral Hepat. 2020 Aug;27(8):762-769. doi: 10.1111/jvh.13317. Epub 2020 May 25. J Viral Hepat. 2020. PMID: 32386099 Review.
Publication types
LinkOut - more resources
Full Text Sources
